Endocrine Abstracts

Introduction: In children, BRAF (e.g. dabrafenib) and MEK (e.g. trametinib) inhibitors are used to treat a range of tumours including low-grade gliomas, Langerhans cell histiocytosis (LCH), and plexiform neurofibromas. However, the ubiquitous nature of the BRAF/MAPK/MEK pathway in various physiological processes means that these treatments are not without their own side effects such as renal tubulopathies (causing hyponatraemia) and hyperglycaemia.Aim: T...